


PHARMACEUTICAL 2020

GALECTIN THERAPEUTICS INC Rank 88 of 362





PHARMACEUTICAL 2020



GALECTIN THERAPEUTICS INC Rank 88 of 362

The relative strengths and weaknesses of GALECTIN THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GALECTIN THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 391% points. The greatest weakness of GALECTIN THERAPEUTICS INC is the variable Revenues, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is -15%, being 288% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	48,209
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,820
Liabilities, Non-Current	52
Other Assets	258
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	144
Property and Equipment	0
Research and Development	7,467
Revenues	0
Selling, General and Administrative Expense	5,971

Output Variable	Value in 1000 USD
Assets	48,467
Liabilities	2,872
Expenses	13,438
Stockholders Equity	45,595
Net Income	-13,294
Comprehensive Net Income	-13,294
Economic Capital Ratio	-15%